Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics has demonstrated strong commercial execution, with recent changes to the Risk Evaluation and Mitigation Strategy (REMS) requirements expected to enhance prescriber adoption of its product, FILSPARI, positively impacting sales. The ongoing acceleration of sparsentan sales, along with a favorable regulatory trajectory in Japan, positions sparsentan as a foundational therapy in the treatment of IgA nephropathy. The cancellation of the Advisory Committee meeting, coupled with the easing of REMS, has received a positive market response, suggesting increased investor confidence in the company's future performance.

Bears say

The financial outlook for Travere Therapeutics Inc exhibits risks primarily due to uncertainties in the company's drug development pathway, with potential challenges stemming from failed or inconclusive clinical trials and difficulties in securing necessary funding. Recent changes in FDA leadership, evolving review practices, and the issuance of Complete Response Letters (CRLs) in real time have contributed to heightened scrutiny within the biotech sector, eliciting caution among investors. The mixed sentiment regarding regulatory decisions in this environment further compounds the potential obstacles to achieving favorable financial milestones, ultimately affecting the company's valuation metrics.

Travere Therapeutics (TVTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 13 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.